The forced swim test has poor accuracy for identifying novel antidepressants.

Autor: Trunnell ER; Laboratory Investigations Department, 501 Front Street, People for the Ethical Treatment of Animals, Norfolk, VA 23510, USA. Electronic address: emilyt@peta.org., Carvalho C; Centro de Filosofia das Ciências da Universidade de Lisboa, Faculdade de Ciências, Campo Grande, Lisboa, Portugal.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2021 Dec; Vol. 26 (12), pp. 2898-2904. Date of Electronic Publication: 2021 Aug 12.
DOI: 10.1016/j.drudis.2021.08.003
Abstrakt: Despite the prevalence of treatment-resistant depression, many pharmaceutical companies have abandoned the development of new antidepressants. Experts have attributed this, in part, to the low quality of preclinical tests available in this field, often citing over-reliance on animal behavioral screens, such as the forced swim test (FST). This retrospective review assessed whether compounds tested in the FST by major pharmaceutical companies were shown to have antidepressant effects in humans. Of 109 compounds identified, only 28% had been explored for antidepressant effects in humans. Of these, there were only three for which the FST appeared to positively predict antidepressant efficacy, but none are currently approved to treat any type of depression. With such poor accuracy for identifying novel antidepressants, the FST might not be a useful screening tool for this purpose.
Competing Interests: Declaration of Competing Interest The authors have no affiliation with any organization with a direct or indirect financial interest in the subject matter discussed in the manuscript.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: